GlassScriptPhysician profile
Aremmia Tanious
NPI 1184638033
$52,575.69
in general payments reported to CMS, 2019-2025
62 companies · $6,889 in 2025
The $6,889 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,622 · 2020: $7,802 · 2021: $7,998 · 2022: $9,403 · 2023: $11K · 2024: $7,842 · 2025: $6,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $6,634 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,100.00 |
| Food and Beverage | $6,634.20 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32,624.63 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Allergan, INC. | $6,984.80 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $1,096.60 | 2019-2025 | Nuplazid |
| Sk Life Science, INC. | $1,085.69 | 2020-2025 | Xcopri |
| Pfizer INC. | $870.65 | 2019-2025 | |
| Lilly USA, LLC | $750.93 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $644.18 | 2019-2023 | Ajovy, Austedo |
| Sunovion Pharmaceuticals INC. | $537.62 | 2019-2022 | |
| Ucb, INC. | $510.18 | 2019-2024 | Briviact, Rystiggo |
| Ani Pharmaceuticals, INC. | $492.85 | 2024-2025 | Purified Cortrophin Gel |
| Eisai INC. | $411.60 | 2020-2025 | |
| Upsher-Smith Laboratories LLC | $389.52 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $372.34 | 2019-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $356.59 | 2023-2025 | Rexulti, Nuedexta |
| Octapharma USA, INC. | $343.92 | 2022-2025 | Panzyga |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aremmia Tanious listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.